US stock movement: Arcutis surged on October 9 due to ZORYVE data and infant eczema news
Bitget异动解读2026/10/09 17:10Arcutis October 9 Surge Analysis
Keywords: ZORYVE data, infant eczema
1. On October 9, the company released data from the Phase II INTEGUMENT-INFANT trial of ZORYVE cream 0.05% in infants aged 3 to under 24 months with atopic dermatitis, showing that once-daily treatment achieved positive results, covering infant patients with limited treatment options.
2. On October 9, the company released new analyses from the ARRECTOR and DERMIS-1/2 trials, indicating that both ZORYVE cream and foam formulations can improve symptoms, skin clearance, and quality of life for patients with psoriasis, covering different areas of the body.
(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Earnings Preview | Applied Materials (AMAT.US) Q4 Results are Certain, the Real Focus is on the Missing 2027 Quantitative Guidance
Applied Materials' high growth in revenue and profit this quarter is already certain. What truly determines the stock price is the guidance for fiscal year 2027, changes in gross margin, and the marginal changes in China-related risks.
Crypto prices
More
